Research Analysts’ Recent Ratings Updates for Sanofi (SNY)

A number of firms have modified their ratings and price targets on shares of Sanofi (NASDAQ: SNY) recently:

• 10/9/2026 – Sanofi is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 10/8/2026 – Sanofi was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 10/5/2026 – Sanofi had its “buy” rating reaffirmed by Berenberg Bank.
• 10/3/2026 – Sanofi was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/1/2026 – Sanofi had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 10/1/2026 – Sanofi had its “neutral” rating reaffirmed by JPMorgan Chase & Co..
• 9/29/2026 – Sanofi had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 9/17/2026 – Sanofi had its “neutral” rating reaffirmed by UBS Group AG.
• 9/10/2026 – Sanofi had its “buy” rating reaffirmed by HSBC Holdings plc.
• 9/8/2026 – Sanofi is now covered by Royal Bank Of Canada. They set a “sector perform” rating on the stock.
• 8/29/2026 – Sanofi was upgraded by Wall Street Zen from “hold” to “buy”.

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.